ACHE
Acetylcholinesterase
As of the edition of 20 October 2026, ACHE (acetylcholinesterase, UniProt P22303) has 23 drugs tested at it and 39 companies on the list, 0 on route A and 9 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P22303
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 80
- Disease areas
- Nervous system; Mental health; Heart and blood vessels; Injuries; Cancer; Immune system; Chemically induced; Digestive system
- Registered trials of its drugs
- 484
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 18 |
| Active | 1 |
| Withdrawn from market | 2 |
| Status not established | 2 |
| Total | 23 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Donepezil | Marketed | Phase 4 | none listed |
| Galantamine | Marketed | Phase 4 | none listed |
| Rivastigmine | Marketed | Phase 4 | none listed |
| Neostigmine | Marketed | Phase 4 | none listed |
| Pyridostigmine | Marketed | Phase 4 | none listed |
| Huperzine a | Active | Phase 4 | none listed |
| Itopride | Marketed | Phase 4 | none listed |
| Acotiamide | Marketed | Phase 4 | none listed |
| Physostigmine | Marketed | Phase 4 | none listed |
| Pralidoxime | Marketed | Phase 2 | none listed |
| Echothiophate | Marketed | Phase 4 | none listed |
| INM-176 | Status not established | Phase 3 | none listed |
12 of 23 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 9 |
| Engaged | 6 |
| Undetermined | 24 |
| Total on the list | 39 |
| Company | Route |
|---|---|
| Novartis | Route B |
| Eisai | Route B |
| Alpha Cognition | Route B |
The other 36 companies at ACHE
In the product39 companies in all; 36 are not named here, and no score is.
See the 39 companies at ACHE, ranked, with the facts behind eachRequest access. Nothing is shown until you do.